jcm-logo

Journal Browser

Journal Browser

Clinical Updates in Bleeding and Thrombotic Disorders

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 30 July 2025 | Viewed by 348

Special Issue Editor

Department of General Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan
Interests: thrombosis; bleeding; hypercoagulability; clot waveform; platelet; coagulation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bleeding tendency and thrombosis due to coagulation abnormalities may cause fatal outcomes, severe complications, or long hospitalization. An early and accurate diagnosis is most important in these pathological states. The coagulation abnormalities include hemophilia A, autoimmune-acquired coagulation deficiency, such as acquired factor VIII (acquired hemophilia A, AHA), factor V, factor X, and factor XIII deficiency, disseminated intravascular coagulation (DIC), thrombotic microangiopathy (TMA), and drug-induced coagulopathy. Thrombotic disorders include venous thromboembolism (VTE), acute cerebral infarction, acute coronary syndrome (ACS), and heparin-induced thrombocytopenia (HIT). These disorders may diagnosed by several tests, such as a clot waveform analysis (CWA), thrombin generation test (TGT), thromboelastogram (TEG), mixing tests, etc.

We are pleased to invite you to our Special Issue, “Clinical Updates in Bleeding and Thrombotic Disorders”. We look forward to receiving your contributions.

Dr. Hideo Wada
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoimmune-acquired coagulation deficiency
  • acquired hemophilia A
  • disseminated intravascular coagulation
  • thrombotic microangiopathy
  • venous thromboembolism
  • acute coronary syndrome
  • clot waveform analysis
  • thrombin generation test
  • thromboelastogram

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 509 KiB  
Article
External Validation of the JAKPOT Score for Diagnosing JAK2-Positive Erythrocytosis: A Retrospective Cohort Study
by Justin Bruni Senecal, Yasmine Madan, Rabia Tahir, Sabina Rajkumar, Wendy Lim, Mark Crowther and Siraj Mithoowani
J. Clin. Med. 2025, 14(15), 5173; https://doi.org/10.3390/jcm14155173 - 22 Jul 2025
Viewed by 196
Abstract
Background/Objectives: Erythrocytosis is a common laboratory abnormality affecting approximately 4% of males and 0.4% of females. The JAKPOT score was recently developed to differentiate primary from secondary erythrocytosis without molecular testing. JAKPOT+ patients meet any of the following criteria: erythrocytes > 6.45 [...] Read more.
Background/Objectives: Erythrocytosis is a common laboratory abnormality affecting approximately 4% of males and 0.4% of females. The JAKPOT score was recently developed to differentiate primary from secondary erythrocytosis without molecular testing. JAKPOT+ patients meet any of the following criteria: erythrocytes > 6.45 × 1012/L, platelets > 350 × 109/L, or neutrophils > 6.2 × 109/L. We aimed to validate this score and identify predictors of JAK2-positive erythrocytosis in a retrospective cohort. Methods: We identified 213 patients (50 female, mean age 57 years) with undifferentiated erythrocytosis, serum erythropoietin (EPO) and JAK2 molecular testing (V617F or exon 12) at a tertiary care center in Hamilton, Canada, between 2017 and 2022. Charts were manually reviewed for laboratory data, comorbidities, demographics, and medications. We evaluated the diagnostic accuracy of EPO, JAKPOT, and a combination of low EPO and JAKPOT (EPO-JAKPOT) for predicting JAK2 mutant erythrocytosis. Multivariate logistic regression analysis was performed to detect predictors of JAK2 mutant erythrocytosis. Results: Forty patients (19%) had JAK2 mutations. Older age (p < 0.01), higher platelet count (p < 0.01), and lower EPO (p < 0.01) were associated with JAK2 mutant erythrocytosis in a multivariate analysis. JAKPOT+ status had a sensitivity of 0.88 (95% CI, 0.73–0.94). Combining low EPO or JAKPOT+ status into a new score (EPO-JAKPOT) increased sensitivity to 0.95 (95% CI, 0.83–0.98). Restricting JAK2 testing to only EPO-JAKPOT+ patients would have led to 55% fewer molecular tests in our cohort. Conclusions: The EPO-JAKPOT score shows promise in excluding JAK2 mutant erythrocytosis without molecular testing, but further prospective validation is warranted. Full article
(This article belongs to the Special Issue Clinical Updates in Bleeding and Thrombotic Disorders)
Show Figures

Figure 1

Back to TopTop